DiaSorin Molecular Iam CBFB MYH11 A/D/E Kit

Iam CBFB-MYH11 Kit

An ultra rapid solution for a one-step differential detection of CBFB-MYH11 Type A, D and E fusion transcripts

Want to know more?

Get in touch
KIT for Oncohematology

Overview

Background

CBFB-MYH11, also known as PEBP2B-MYH11, inv(16), t(16;16) is a recurrent genetic abnormality especially in adult Acute Myeloid Leukemia (10% of all de novo AML). This translocation is also one of the most frequently balanced chromosomal translocations found in patients with therapy-related AML (t-AML). Although this genetic alteration is associated with a good prognosis, 30%-40% of these patients experience relapse and its rapid molecular identification is considered crucial for patients’ management and therapeutic decisions.

Why to choose it

Comprehensive molecular identification of common (Type A) and rare (Type D and E) isoforms of CBFB-MYH11 fusion in a single rapid step.

For use on

Benefits

DiaSorin Molecular Iam CBFB MYH11 A/D/E Kit
Ultra Rapid

Identification of positive samples in less than 20 min, starting from extracted RNA

Results in < 20 minutes
Easy to
set up

From RNA to result in a one-step solution

Retrotrascription, amplification and data elaboration happen on board the LIAISONTM IAM in a close tube, one-step format.

Lab specialist daily work
Highly reliable

Internal endogenous control and quality controls are included to allow validation of results

Highly specific

No false positive results and absence of primer dimers

Validated on 614 replicates

The Analytical Specificity has been established on negative cell line RNA extracted by both the Qiagen RNeasyTM kit and modified TrizolTM.

 

Sample type Replicates % Analytical Specificity
Sample typeCell lines Replicates400 % Analytical Specificity100%
Sample typeNTC Replicates214 % Analytical Specificity99,5%
Lab specialist working
Clinically validated

100% concordance with the traditional RT-PCR (Biomed Protocol*, by Van Dongen et al)
*Leukemia. 1999 Dec;13(12):1901-28.

67 clinical samples

The analysis has been performed on clinical samples using RNA extracted by QiagenTM RNeasyTM kit or modified TRIzolTM protocol and demonstrates a complete concordance with the reference method.

Sample status No.Samples % Agreement with PCR
(BIOMED protocol)
Sample statusCBFB-MYH11 A positive No.Samples28 % Agreement with PCR 100%
Sample statusCBFB-MYH11 D or E positive No.Samples9 % Agreement with PCR 100%
Sample statusCBFB-MYH11 negative No.Samples30 % Agreement with PCR 100%
Robust

Superior robustness to inhibitors, RNA degradation and suboptimal target quantities

The intrinsic robustness of the enzyme employed in Q-LAMP results in an enhanced robustness versus the classical inhibitor factors of PCR.

Lab scientist with vials
Superiority versus PCR

Q-LAMP is a very rapid, easy, accurate, convenient and robust method for detection of CBFB-MYH11 translocations

Q-LAMP RT-PCR (Biomed)
SubjectRNA input Q-LAMP500 ng/rx robust down to 25 ng/rx RT-PCR (Biomed)1μg/rx
SubjectSteps Q-LAMP1 RT-PCR (Biomed)3
SubjectAssay format Q-LAMPMULTIPLEX RT-PCR (Biomed)SIMPLEX
SubjectControl of reaction Q-LAMPINTERNAL RT-PCR (Biomed)EXTERNAL
SubjectRobustness Q-LAMP– to chemical contamination
– to PCR inhibitors
– to degraded samples
RT-PCR (Biomed)To chemical contamination
SubjectResult interpretation Q-LAMPOBJECTIVE RT-PCR (Biomed)SUBJECTIVE
SubjectTime to result Q-LAMP40min RT-PCR (Biomed)3h 30min

Ordering info

Product Code Reactions
Product

Iam CBFB-MYH11 (A/D/E)

Code V36CBFB Reactions 54

Do you want to place an order or request a trial?

Discover more

Our repository

All the answers you need.
Access our database to find:
instructions for use, safety data sheets,
assay protocols and more.

Access our repository